Business
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference
Eleven Poster Presentations Include New Analyses of ARAZLO®, DUOBRII®, and IDP-126...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology ConferenceEleven Poster Presentations Include New Analyses of ARAZLO®, DUOBRII®, and IDP-126 GelLAVAL, QC / ACCESSWIRE / October 20, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (\"Bausch Health\") and its dermatology business, Ortho Dermatologics, today announced the presentation of eleven posters during the Fall Clinical Dermatology Conference, which takes place Oct. 20-23, 2022 in Las Vegas, Nev. The presentations will feature new data around ARAZLO® (tazarotene) Lotion, 0.045%, DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, and the investigational medicine IDP-126 Gel-a combination retinoid, antibacterial and antibiotic topical. Two other presentations are adaptations featuring research on SILIQ® (brodalumab) Injection, 210 mg/1.5 mL. Please see below for warning about suicidal ideation and behavior with SILIQ. There will also be five encore presentations, including a systemic review of onychomycosis dermatophytoma treatment.\"Ortho Dermatologics remains committed to research to ensure the safety and efficacy of our portfolio with patients top of mind,\" said Richard Lajoie, vice president and general manager, Ortho Dermatologics. \"At this year's Fall Clinical Dermatology Conference, we look forward to the opportunity to personally connect with dermatologists to share new data on our investigational acne medicine, IDP-126 Gel, as well as new analyses on two of our prominent acne and psoriasis medications, ARAZLO® and DUOBRII®.\"The complete list of Ortho Dermatologics' poster presentations is as follows:ARAZLO® (tazarotene) Lotion, 0.045%\"Impact of Seasonal Variation on the Efficacy and Safety of Tazarotene 0.045% Lotion for Acne: Post Hoc Analysis of Pooled Phase 3 Data.\" Draelos et al.\"Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Tolerability, and Spreadability.\" Kircik et al.DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%\"Use of Combination Halobetasol Propionate/Tazarotene Lotion in Difficult-to-Treat Psoriasis and TNF-α Mechanism of Action.\" Kircik et al.\"Efficacy and Safety of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis from Real-World Patient Perspectives\" Lain et al.\"Fixed-Com...